Savara's Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP
Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.
"We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP," said Matt Pauls, Chair and CEO, Savara. "We are also keen to increase awareness and understanding of this rare and chronic lung disease through our Industry Theater with two aPAP experts."
ATS 2024 Accepted Abstracts:
Savara
701: Healthcare Burden of Pulmonary Alveolar Proteinosis
Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant
Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT
Trillium Health
702: Development of a Novel Laboratory Test for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Individuals At-Risk for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant
Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT
The abstracts will be published in a supplement of theAmerican Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024. For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php.
Industry Theater:
Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
Sunday, May 19, 2024, 1:15-2:00 PM PDT
Bruce Trapnell, M.D., M.S. and Tisha Wang, M.D. will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.